Menu
Search
|

Menu

Close
X

OncoMed Pharmaceuticals Inc OMED.OQ (NASDAQ Stock Exchange Global Select Market)

0.89 USD
+0.02 (+2.76%)
As of Feb 22
chart
Previous Close 0.87
Open 0.85
Volume 119,832
3m Avg Volume 86,972
Today’s High 0.93
Today’s Low 0.83
52 Week High 3.61
52 Week Low 0.55
Shares Outstanding (mil) 37.63
Market Capitalization (mil) 164.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
34
FY17
38
FY16
25
EPS (USD)
FY18
-0.091
FY17
-1.075
FY16
-3.182
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
6.68
6.29
Price to Book (MRQ)
vs sector
--
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
--
16.12
LT Debt to Equity (MRQ)
vs sector
--
11.38
Return on Investment (TTM)
vs sector
-75.79
14.45
Return on Equity (TTM)
vs sector
--
15.96

EXECUTIVE LEADERSHIP

Perry Karsen
Chairman of the Board, Since 2018
Salary: --
Bonus: --
John Lewicki
President, Chief Executive Officer, Director, Since 2018
Salary: $364,727.00
Bonus: --
Austin Gurney
Senior Vice President, Molecular and Cellular Biology, Since
Salary: --
Bonus: --
Tim Hoey
Senior Vice President, Cancer Biology, Since
Salary: --
Bonus: --
Yvonne Li
Vice President - Finance, Controller and Administration, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

800 Chesapeake Dr
REDWOOD CITY   CA   94063-4748

Phone: +1650.9958200

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

SPONSORED STORIES